About: QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin
Creator	Daily, Johanna Fisher, John Biase, Luigi Di Biase, Luigi Ferrick, Kevin Greige, Nicolas Hsia, Brian Khokhar, Ahmed Krumerman, Andrew Org, Jfisher@montefiore Quiroz, Jose
Source	Medline; PMC
abstract	PURPOSE: Hydroxychloroquine, chloroquine, and azithromycin have been used for treatment of COVID-19, but may cause QT prolongation. Minority populations are disproportionately impacted by COVID-19. This study evaluates the risk of QT prolongation and subsequent outcomes after administration of these medications in largely underrepresented minority COVID-19 patients. METHODS: We conducted an observational study on hospitalized COVID-19 patients in the Montefiore Health System (Bronx, NY). We examined electrocardiograms (ECG) pre/post-medication initiation to evaluate QTc, HR, QRS duration, and presence of other arrhythmias. RESULTS: One hundred five patients (mean age 67 years; 44.8% F) were analyzed. The median time from the first dose of any treatment to post-medication ECG was 2 days (IQR: 1–3). QTc in men increased from baseline (440 vs 455 ms, p < 0.001), as well as in women (438 vs 463 ms, p < 0.001). The proportion of patients with QT prolongation increased significantly (14.3% vs 34.3%, p < 0.001) even when adjusted for electrolyte abnormalities. The number of patients whose QTc > 500 ms was significantly increased after treatment (16.2% vs. 4.8%, p < 0.01). Patients with either QTc > 500 ms or an increase of 60 ms had a higher frequency of death (47.6% vs. 22.6%, p = 0.02) with an odds ratio of 3.1 (95% CI: 1.1–8.7). Adjusting for race/ethnicity yielded no significant associations. CONCLUSIONS: Hydroxychloroquine, chloroquine, and/or azithromycin were associated with QTc prolongation but did not result in fatal arrhythmias. Our findings suggest that any harm is unlikely to outweigh potential benefits of treatment. Careful risk-benefit analyses for individual patients should guide the use of these medications. Randomized control trials are necessary to evaluate their efficacies.
has issue date	2020-07-11(xsd:dateTime)
bibo:doi	10.1007/s10840-020-00822-x
bibo:pmid	32654098
has license	no-cc
sha1sum (hex)	1e592dd4ad60161f488f8f027ffabb300bd653f6
schema:url	https://doi.org/10.1007/s10840-020-00822-x
resource representing a document's title	QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin
has PubMed Central identifier	PMC7352082
has PubMed identifier	32654098
schema:publication	J Interv Card Electrophysiol
resource representing a document's body	covid:1e592dd4ad60161f488f8f027ffabb300bd653f6#body_text
is schema:about of	named entity 'QT prolongation' named entity 'MEDICATIONS' named entity 'SUBSEQUENT' covid:arg/1e592dd4ad60161f488f8f027ffabb300bd653f6 named entity 'Hydroxychloroquine' named entity 'COVID' named entity 'QTc' named entity 'Institutional Review Board' named entity 'ventricular tachycardia' named entity 'ethnicity' named entity 'risk factor' named entity 'ventricular tachycardia' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'diagnostic testing' named entity 'QTc' named entity 'Arrhythmia' named entity 'RBBB' named entity 'intubation' named entity 'arrhythmia' named entity 'Bronx, New York' named entity 'viral load' named entity 'QT prolongation' named entity '5.7%' named entity 'atrial fibrillation' named entity '12-lead ECG' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'hydroxychloroquine' named entity 'ventricular tachyarrhythmia' named entity 'telemetry' named entity 'ECG' named entity 'calcium' named entity 'QT prolongation' named entity 'QT interval' named entity 'Wilcoxon signed-rank test' named entity 'Montefiore Health System' named entity 'intubation' named entity 'ECG' named entity 'QT prolongation' named entity 'ECG' named entity 'cardiovascular' named entity 'mEq/L' named entity 'Stata' named entity 'lymphopenia' named entity 'sequential organ failure assessment score' named entity 'coronavirus' named entity 'cardiomyopathy' named entity 'McNemar's test' named entity 'QTc' named entity 'QTc prolongation' named entity 'Treatment regimens' named entity 'COVID-19' named entity 'QTc prolongation' named entity 'QTc' named entity 'tachycardia' named entity 'QTc prolongation' named entity 'QTc' named entity 'QTc' named entity 'infection' named entity 'ECG' named entity 'dyspnea' named entity 'hydroxychloroquine' named entity 'electrolyte imbalance' named entity 'hypoxia' named entity 'RBBB' named entity 'Montefiore Health System' named entity 'QTc' named entity 'diabetes mellitus' named entity 'chronic kidney disease' named entity 'chloroquine' named entity 'Albert Einstein College of Medicine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software